- CONDENSED BI-HETEROCYCLES AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE
-
Provided are compounds of Formula (I): Formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, A1, B1, B2, Q1 and Q2 are as defined herein; and methods for their use and production.
- -
-
Page/Page column 78
(2021/05/07)
-
- INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE
-
Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and methods for their use and production.
- -
-
-
- ISOQUINOLINE COMPOUNDS AND USES THEREOF
-
Isoquinoline compounds of formula (I) variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the isoquinoline compounds.
- -
-
-
- 8-AMINOISOQUINOLINE CompoundS AND USES THEREOF
-
3-Carbonylamino-8-aminoisoquinoline Compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The Compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the 3-carbonylamino-8-aminoisoquinoline Compounds.
- -
-
-
- ISOQUINOLINE COMPOUNDS FOR THE TREATMENT OF CANCER
-
3-Carbonylaminoisoquinoline compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the 3-carbonylaminoisoquinoline compounds.
- -
-
-
- HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF HPK1
-
Disclosed are Hematopoietic Progenitor Kinase 1 (HPK1) degradation / disruption compounds including a HPK1 ligand, a degradation / disruption tag and a linker, and methods for use of such compounds in the treatment of HPK1-mediated diseases.
- -
-
Page/Page column 257
(2020/11/23)
-
- INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE
-
Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, methods for use as Bruton's tyrosine kinase and methods of production.
- -
-
-
- ISOQUINOLINES AS INHIBITORS OF HPK1
-
Isoquinoline compounds and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibitng HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the isoquinoline compounds.
- -
-
-
- Cyclic amine compounds
-
The present invention relates to pharmaceutical agents which are agents for the prophylaxis or treatment of hypogonadism, male climacteric disorder, frailty, cachexia or osteoporosis; the pharmaceutical agents frailty suppressants, muscle strength enhance
- -
-
Page/Page column 49
(2009/03/07)
-
- SUBSTITUTED PYRAZOLE DERIVATIVES
-
The present invention provides a novel pyrazole derivative and an androgen receptor antagonist containing the derivative. The present invention provides a compound represented by the formula (I′) wherein R1 is a hydrogen atom, a group via a carbon atom, a group via a nitrogen atom, a group via an oxygen atom, or a group via a sulfur atom; R2 is a phenyl group having cyano (the phenyl group may further have substituent(s) other than cyano); R3 is a hydrogen atom, a group via a carbon atom, a group via a nitrogen atom, a group via an oxygen atom, or a group via a sulfur atom; R4 is a cyclic group optionally having substituent(s); and X is methylene optionally having substituent(s), or CO, or a salt thereof.
- -
-
Page/Page column 38
(2009/10/31)
-